Abstract 248P
Background
Many patients concern the body imbalance after mastectomy and it is often cited as justification for immediate-breast reconstruction (IBR). However, few studies have investigated the impact of mastectomy or IBR on scoliosis, and analyzed only a small number of patients. We investigated whether mastectomy impacts spine alignment compared to IBR with a large cohort.
Methods
We retrospectively reviewed the patients who underwent breast cancer surgery between 2004 and 2018 at a single institution. Using the deep learning-based algorithm (DeepNoid Inc.), we collected Cobb's angle from chest posteroanterior x-rays at three time points: pre-operation, postoperative one-year, and five-years. Patients who underwent bilateral surgery, delayed-reconstruction, or LD-flap were excluded.
Results
Totally 6246 patients were included: 3442 (55.1%), 1911 (30.6%), and 893 (14.3%) patients underwent breast-conservation surgery (BCS), mastectomy without IBR, and IBR, respectively. At postoperative five-years, the mastectomy group showed the significantly greater change in Cobb's angle compared to both the BCS (p<0.001) and IBR (p=0.004) groups, while there was no significant difference between the BCS and IBR groups (p=0.347). After adjusting for other clinicopathologic variables, operation methods, adjuvant hormone treatments, and the direction of cancer remained significant factors affecting vertebral alignment. However, there was no relationship between the excised breast weights and Cobb's angle. Propensity score matching also showed that mastectomy group has greater change in angle compared to the other groups (vs. BCS, p=0.041; vs. IBR, p=0.047). Cobb’s angle was more evidence among patients under 50 years old (p=0.016) and who administered hormone treatment (p=0.009). Lastly, significantly more patients experienced lumbar pain after mastectomy (8.4%) than after BCS (6.7%) or IBR (4.1%) during the surveillance (p<0.001).
Conclusions
This is the largest study that showed the significant change in thoracic spine alignment after mastectomy compared to BCS and IBR. The results would provide the evidence on recommending breast reconstruction especially for young patients and educating post-mastectomy postural correction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Seoul National University Hospital.
Disclosure
H. Lee; W. Han: Financial Interests, Personal, Stocks or ownership, Not relevant to this study: DCGen. All other authors have declared no conflicts of interest.
Resources from the same session
242P - Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Presenter: Nicholas McAndrew
Session: Poster session 13
243P - Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Presenter: Luca Arecco
Session: Poster session 13
244P - Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Presenter: Yang Zhengjun
Session: Poster session 13
245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Presenter: Paolo Tarantino
Session: Poster session 13
246P - Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial
Presenter: Anna C. Weiss
Session: Poster session 13
247P - Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Presenter: Luiz Felipe de Almeida
Session: Poster session 13
249P - Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Presenter: Laura Michel
Session: Poster session 13
250P - Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Presenter: Fresia Pareja
Session: Poster session 13